<DOC>
	<DOCNO>NCT01328951</DOCNO>
	<brief_summary>This double-blind , placebo-controlled study evaluate benefit first-line maintenance erlotinib ( Tarceva ) versus erlotinib time disease progression participant advance NSCLC progress follow 4 cycle platinum based-chemotherapy whose tumor harbor epidermal growth factor receptor ( EGFR ) -activating mutation . Participants randomize receive either erlotinib 150 milligram ( mg ) orally ( PO ) daily placebo . Participants progress placebo receive erlotinib 150 mg PO daily second-line therapy , progress erlotinib may switch non-investigational , second-line chemotherapy . Treatments continue disease progression , death , unacceptable toxicity . Participants may also enter final Survival Follow-Up ( SFU ) period upon treatment discontinuation .</brief_summary>
	<brief_title>A Study First-line Maintenance Erlotinib Versus Erlotinib Disease Progression Participants With Advanced Non-Small Cell Lung Cancer ( NSCLC ) Who Have Not Progressed Following Platinum-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adults great equal ( ≥ ) 18 year age , legal age consent great 18 Advanced recurrent ( Stage IIIB ) metastatic ( Stage IV ) NSCLC Completion 4 cycle platinumbased chemotherapy without progression ( end last chemotherapy cycle less equal [ ≤ ] 28 day prior randomization ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prior exposure agent direct human epidermal growth factor receptor ( HER ) axis ( e.g . erlotinib , gefitinib , cetuximab ) Participants whose tumor harbor EGFRactivating mutation Prior chemotherapy therapy systemic antineoplastic therapy advance disease Screening Use pemetrexed maintenance setting ( pemetrexed allow chemotherapy runin ) Participants undergone complete tumor resection respond platinumbased chemotherapy Screening phase Any malignancy within 5 year , except curatively resect carcinoma situ cervix , basal squamous cell skin cancer , ductal carcinoma situ , organconfined prostate cancer Central nervous system ( CNS ) metastases spinal cord compression definitely treat surgery and/or radiation , treat CNS metastasis spinal cord compression without stable disease ≥2 month Human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C infection Any inflammatory change surface eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>